MAP Kinase Kinase 2

• 

  Subject Areas on Research

  • Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. 
  • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. 
  • MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. 
  • MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease. 
  • Negative regulation of mTOR activation by diacylglycerol kinases.